dc.creator | Barcelona, Pablo Federico | |
dc.creator | Sitaras, Nicholas | |
dc.creator | Galan, Alba | |
dc.creator | Esquiva, Gema | |
dc.creator | Jmaeff, Sean | |
dc.creator | Jian, Yiman | |
dc.creator | Sarunic, Marinko V. | |
dc.creator | Cuenca, Nicolas | |
dc.creator | Sapieha, Przemyslaw | |
dc.creator | Saragovi, H. Uri | |
dc.date.accessioned | 2018-06-11T13:52:09Z | |
dc.date.accessioned | 2018-11-06T11:29:00Z | |
dc.date.available | 2018-06-11T13:52:09Z | |
dc.date.available | 2018-11-06T11:29:00Z | |
dc.date.created | 2018-06-11T13:52:09Z | |
dc.date.issued | 2016-08 | |
dc.identifier | Barcelona, Pablo Federico; Sitaras, Nicholas; Galan, Alba; Esquiva, Gema; Jmaeff, Sean; et al.; p75NTR and its ligand proNGF activate paracrine mechanisms etiological to the vascular, inflammatory, and neurodegenerative pathologies of diabetic retinopathy; Society for Neuroscience; Journal of Neuroscience; 36; 34; 8-2016; 8826-8841 | |
dc.identifier | 0270-6474 | |
dc.identifier | http://hdl.handle.net/11336/48048 | |
dc.identifier | 1529-2401 | |
dc.identifier | CONICET Digital | |
dc.identifier | CONICET | |
dc.identifier.uri | http://repositorioslatinoamericanos.uchile.cl/handle/2250/1853023 | |
dc.description.abstract | In many diseases, expression and ligand-dependent activity of the p75NTR receptor can promote pericyte and vascular dysfunction, inflammation, glial activation, and neurodegeneration. Diabetic retinopathy (DR) is characterized by all of these pathological events. However, the mechanisms by which p75NTR may be implicated at each stage of DR pathology remain poorly understood. Here, in a streptozotocin mouse model of diabetic retinopathy, we report that p75NTR is up-regulated very early in glia and in pericytes to mediate ligand-dependent induction of inflammatory cytokines, disruption of the neuro-glia-vascular unit, promotion of blood-retina-barrier breakdown, edema, and neuronal death. In a mouse model of oxygen-induced retinopathy, mimicking proliferative DR, p75NTR?dependent inflammation leads to ischemia and pathological angiogenesis through Semaphorin 3A. The acute use of antagonists of p75NTR or antagonists of the ligand proNGF suppresses each distinct phase of pathology, ameliorate disease, and prevent disease progression. Thus, our study documents novel disease mechanisms, and validates druggable targets for diabetic retinopathy. | |
dc.language | eng | |
dc.publisher | Society for Neuroscience | |
dc.relation | info:eu-repo/semantics/altIdentifier/url/http://www.jneurosci.org/content/36/34/8826 | |
dc.relation | info:eu-repo/semantics/altIdentifier/doi/https://doi.org/10.1523/JNEUROSCI.4278-15.2016 | |
dc.rights | https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | P75 NTR | |
dc.subject | ALFA2M | |
dc.subject | DIABETES | |
dc.subject | PRONGF | |
dc.title | p75NTR and its ligand proNGF activate paracrine mechanisms etiological to the vascular, inflammatory, and neurodegenerative pathologies of diabetic retinopathy | |
dc.type | Artículos de revistas | |
dc.type | Artículos de revistas | |
dc.type | Artículos de revistas | |